Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of "Buy" by Brokerages

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have received a consensus recommendation of "Buy" from the six ratings firms that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $10.67.

Several analysts recently weighed in on the company. Raymond James set a $7.00 price objective on Aquestive Therapeutics in a research report on Friday, March 7th. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Thursday, May 15th. Alliance Global Partners reiterated a "buy" rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Finally, Lake Street Capital dropped their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, March 7th.

Aquestive Therapeutics Price Performance

Aquestive Therapeutics stock traded up $0.06 during mid-day trading on Tuesday, reaching $2.35. 1,263,613 shares of the company were exchanged, compared to its average volume of 1,519,334. The company has a fifty day simple moving average of $2.71 and a 200-day simple moving average of $3.25. Aquestive Therapeutics has a 12 month low of $2.12 and a 12 month high of $5.80. The firm has a market cap of $233.42 million, a PE ratio of -5.22 and a beta of 2.02.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The company had revenue of $8.72 million for the quarter, compared to analyst estimates of $12.23 million. Sell-side analysts anticipate that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Aquestive Therapeutics by 1.9% during the fourth quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company's stock worth $15,474,000 after purchasing an additional 82,958 shares during the period. Pale Fire Capital SE increased its stake in shares of Aquestive Therapeutics by 154.1% in the first quarter. Pale Fire Capital SE now owns 1,335,684 shares of the company's stock valued at $3,873,000 after buying an additional 809,928 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of Aquestive Therapeutics by 7.6% in the first quarter. Janney Montgomery Scott LLC now owns 1,059,760 shares of the company's stock valued at $3,073,000 after buying an additional 75,275 shares during the period. Bank of America Corp DE increased its stake in shares of Aquestive Therapeutics by 905.2% in the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock valued at $2,457,000 after buying an additional 621,614 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Aquestive Therapeutics by 3.1% in the fourth quarter. Northern Trust Corp now owns 599,812 shares of the company's stock valued at $2,135,000 after buying an additional 18,199 shares during the period. Institutional investors and hedge funds own 32.45% of the company's stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.